Use of liposomal wnt compositions to enhance osseointegration

ABSTRACT

Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.

CROSS REFERENCE

This application claims benefit and is a Continuation of applicationSer. No. 16/184,705, filed Nov. 8, 2018, which is a Continuation ofapplication Ser. No. 14/337,718 filed Jul. 22, 2014, now patented U.S.Pat. No. 10,183,057, issued on Jan. 22, 2019, which is a Continuation ofapplication Ser. No. 13/199,820 filed on Sep. 9, 2011, now patented U.S.Pat. No. 8,809,272, issued on Aug. 19, 2014, which claims benefit ofU.S. Provisional Patent Application No. 61/403,122, filed Sep. 9, 2010,which applications are incorporated herein by reference in theirentirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

A Sequence Listing is provided herewith as a Sequence Listing XML,STAN-777CON3_Seq Listing created on Aug. 24, 2022, and having a size ofenter size in bytes 9,710 bytes. The contents of the Sequence ListingXML are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

Orthopedic and dental implants are used for a variety of joint and teethreplacements and to promote bone repair in humans and animals,particularly for hip and knee joint and tooth replacements. However,although many individuals experience uncomplicated healing andrestoration of function, there is also a high rate of complications,estimated at 10-20% for total joint replacements. The majority of thesefailures and subsequent revision surgeries are made necessary by failureat the implant-bone interface.

Orthopedic and dental implants are made of materials which arerelatively inert (“alloplastic” materials), typically a combination ofmetallic and ceramic or plastic materials. Previous approaches toimprove the outcomes of orthopedic implant surgeries have mainly focusedon physical changes to the implant surface that result in increased boneformation. These approaches include using implants with porous metallicsurfaces to promote bone ingrowth and spraying implants withhydroxyapatite plasma. Approaches using dental implants have alsoincluded the use of topographically-enhanced titanium surfaces in whichsurface roughness is imparted by a method such as grit blasting, acidetching, or oxidation.

In an effort to promote osseointegration, implant surfaces haveundergone major alterations. For example, short peptides containing anarginine-glycine-aspartic acid (RGD) sequences have been attached toimplant surfaces because cells utilize RGD sequences to attach to theextracellular matrix. Investigators have attempted to recreate this cellattachment to the modified implant surface but this strategy hasresulted in only modest increases in implant osseointegration andmechanical fixation. Alternatively, in an attempt to stimulate bloodvessel ingrowth around implants their surfaces have been coated with acoating containing the angiogenic growth factor VEGF.

Another strategy employed to stimulate osseointegration is tonano-texture the implant surface. The rationale behind this strategy isthat texturing increases surface area and therefore prevents the implantfrom “sliding” against cells in the peri-implant environment. Inclinical trials, however, nano-texturing does not result in measureablebenefits.

The use of protein-based approaches to stimulate implantosseointegration has also been under intense investigation. Bonemorphogenetic proteins induce robust endochondral ossification inskeletal fractures and they have also been employed in an effort tostimulate direct bone formation around implants. While in vitro resultshave been encouraging, in vivo data are less convincing. RecombinantBMPs inhibit osteogenic differentiation of cells in the bone marrowcavity and consequently, are contraindicated for implantosseointegration. See Sykaras et al. (2004) Clin Oral Investig 8(4):196-205; and Minear et al. (2010) Journal of Bone and Mineral Research25(6): 1196-207.

Wnt proteins form a family of highly conserved secreted signalingmolecules that regulate cell-to-cell interactions during embryogenesis.Wnt genes and Wnt signaling are also implicated in cancer. Insights intothe mechanisms of Wnt action have emerged from several systems: geneticsin Drosophila and Caenorhabditis elegans; biochemistry in cell cultureand ectopic gene expression in Xenopus embryos. Many Wnt genes in themouse have been mutated, leading to very specific developmental defects.As currently understood, Wnt proteins bind to receptors of the Frizzledfamily on the cell surface. Through several cytoplasmic relaycomponents, the signal is transduced to beta-catenin, which then entersthe nucleus and forms a complex with TCF to activate transcription ofWnt target genes.

Wnt glycoproteins are thought to function as paracrine or autocrinesignals active in several primitive cell types. The Wnt growth factorfamily includes more than 19 genes identified in the mouse and inhumans. The Wnt-1 proto-oncogene (int-1) was originally identified frommammary tumors induced by mouse mammary tumor virus (MMTV) due to aninsertion of viral DNA sequence (Nusse and Varmus (1982) Cell 31:99-109). Expression of Wnt proteins varies, but is often associated withdevelopmental process, for example in embryonic and fetal tissues. Wntsmay play a role in local cell signaling. Biochemical studies have shownthat much of the secreted Wnt protein can be found associated with thecell surface or extracellular matrix rather than freely diffusible inthe medium.

Wnt signaling is involved in numerous events in animal development,including the proliferation of stem cells and the specification of theneural crest. Wnt proteins are therefore potentially important reagentsin expanding specific cell types, and in treatment of conditions invivo.

Publications

The biological activity of soluble wingless protein is described in vanLeeuwen et al. (1994) Nature 24: 368(6469): 342-4. Biochemicalcharacterization of Wnt-frizzled interactions using a soluble,biologically active vertebrate Wnt protein is described by Hsieh et al.(1999) Proc Natl Acad Sci U S A 96(7): 3546-51. Bradley et al. (1995)Mol Cell Biol 15(8): 4616-22 describe a soluble form of wnt protein withmitogenic activity.

SUMMARY OF THE INVENTION

Methods and compositions are provided for the therapeutic use of Wntproteins in enhancing osteogenesis, e.g. in acceleratingosseointegration of implants, improving bone repair following an injury,in the treatment of bone disease, etc. It is shown herein that a pulseof Wnt activity significantly accelerates bone regeneration by takingadvantage of the early Wnt-dependent proliferative effect but avoidingdetrimental consequences of persistent Wnt activation. It is alsosurprisingly found that Wnt in aqueous phase was ineffective incomparison with a formulation where the Wnt protein was inserted in thenon-aqueous phase of a lipid structure.

In some embodiments of the invention, the methods provide an individualwith a stable orthopedic or dental implant, where the method comprisesintroducing an orthopedic or dental implant into an individual in needthereof; and contacting the site of the implant with a wnt formulationcomprising wnt is inserted in the non-aqueous phase of a lipidstructure, where the site of implant includes, without limitation, theperi-implant space. The methods speed osseointegration and extend thefunctional lifespan of orthopedic and dental implants. This treatmenttransiently amplifies the normal Wnt response to injury, which occursafter drilling and importantly for this work, implant placement.Advantages include stimulation of osteo-progenitor cell proliferation inperi-implant tissues, e.g. around dental and orthopedic implants,accelerated bone apposition to the implant, leading to faster healingtimes and stronger osseointegration; and a maintenance of theseadvantages for extended periods of time. This creates a safety marginfor the implant because at any given post surgical time, increasing thebone formation around an implant acts to prevent the failure of thatimplant upon loading. This safety margin not only protects from implantfailure at certain loads, but also allows the implant to be loaded at anearlier time point.

The wnt formulation may be delivered directly to the site of theimplant. The wnt formulation is provided immediately before, during orafter the implant is introduced, and in some embodiments is deliveredwithin 1, 2, 3, 4, 5, 6, 7 days following introduction. The wntformulation may be transiently provided over a short, defined period oftime, for example as a single bolus, as a continuous injection for ashort period of time, e.g. not more than about 48 hours, not more thanabout 24 hours, not more than about 12 hours, etc., as repeated bolusdoses for a short period of time, e.g. not more than about 48 hours, notmore than about 24 hours, not more than about 12 hours, etc., and thelike.

The methods of the invention may be applied to a wide variety ofimplants in the orthopedic and dental fields, including, for examples,hip, knee, spine and dental implants. In addition to injection of wnt,the implant may be coated with a wnt formulation of the invention priorto introduction, for example where the implant acts as a receptacle forthe formulation, which is extruded or released at the appropriate timeafter initial inflammation has subsided; where a reservoir of the wntformulation is implanted in conjunction with the implant, and the like.

In some embodiments of the invention, a pharmaceutical composition forin vivo administration to enhance osteogenesis comprises atherapeutically effective dose of a Wnt protein, where the Wnt proteinis inserted in the non-aqueous phase of a lipid structure, e.g. in thesurface of a liposome, micelle, lipid raft, etc., in an emulsion, andthe like. In some embodiments the Wnt protein is presented in its activeconformation on an outer liposome membrane or micelle. Where the lipidstructure is a liposome it is desirable that the Wnt protein not beencapsulated within the liposome, e.g. in an aqueous phase. Thelipid-containing particles typically display copies of a wntpolypeptide, the particles comprising at least one copy of a wntpolypeptide bearing at least one lipid moiety, where the compositioncontains at least 50% of the Wnt polypeptides displayed on the exteriorsurface of the particle.

In some embodiments of the invention, the Wnt protein is a mammalianprotein, including, without limitation, human Wnt proteins, e.g. Wnt3A.The Wnt compositions find use in a variety of therapeutic methods.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is best understood from the following detailed descriptionwhen read in conjunction with the accompanying drawings. The patent orapplication file contains at least one drawing executed in color. Copiesof this patent or patent application publication with color drawing(s)will be provided by the Office upon request and payment of the necessaryfee. It is emphasized that, according to common practice, the variousfeatures of the drawings are not to-scale. On the contrary, thedimensions of the various features are arbitrarily expanded or reducedfor clarity. Included in the drawings are the following figures.

FIG. 1A-1I: Wnt responsive osteo-progenitor cells populate the endostealsurface. FIG. 1A Pentachrome staining of periosteal and endostealsurfaces adult tibiae, sectioned in the transverse plane. FIG. 1B Xgalstaining of the tibia from an adult Axin2^(LacZ/+) mouse identifies theendosteum as a site of endogenous Wnt signaling. FIG. 1C Cells liningthe bony trabeculae exhibit Xgal staining. FIG. 1D Cells on theendosteal surface exhibit alkaline phosphatase (ALP) activity. FIG. 1EVery few cells exhibit tartrate resistance acid phosphatase (TRAP)activity on the endosteal surfaces. FIG. 1F Platelet endothelial celladhesion molecule (PECAM) immunopositive cells are detected throughoutthe bone marrow cavity. In situ hybridization for FIG. 1G Runx2, FIG. 1HCollagen type I (Col I), and FIG. 1I Osteocalcin (Oc) in the endosteumand bone marrow cavity of the tibia. Abbreviations: by, blood vessel;cb, cortical bone; en, endosteum; po, periosteum, *trabeculae projectinginto the marrow cavity. Scale bar for all panels except C=50 μm; inC,=10 μm.

FIG. 2A-2J: Inhibition of Wnt signaling results in bone resorption. FIG.2A Tartrate resistance acid phosphatase (TRAP) activity in theendosteum, 48 h after injection of a control adenovirus that expressesthe coding region of IgG2α Fc. FIG. 2B TRAP activity in the endosteum,48 h after injection of adenovirus expressing coding region for Dkk1.FIG. 2C TRAP activity of periosteum from control tibiae at 48 h timepoint. FIG. 2D TRAP activity of periosteum from Ad-Dkk1 injected tibiae,48 h time point. FIG. 2E Platelet endothelial adhesion molecule (PECAM)staining in bone marrow after injection of Ad-Fc control, 48 h timepoint. FIG. 2F PECAM staining in bone marrow after Ad-Dkk1 delivery, 48h time point. FIG. 2G Alkaline phosphatase (ALP) activity of endosteumafter Ad-Fc injection. FIG. 2H ALP activity of endosteum after Ad-Dkk1injection. FIG. 2I ALP activity of periosteum after injection of Ad-Fc.FIG. 2J ALP activity of periosteum after delivery of Ad-Dkk1.Abbreviations: bm, bone marrow; cb, cortical bone; po, periosteum; m,muscle. Scale bar for all panels=50 μm.

FIG. 3A-3E: liposomal Wnt3a stimulates osteoprogenitor cellproliferation FIG. 3A Murine tibia with pin implant in place; theinjection of methylene blue dye indicates position of implant tip. FIG.3B Scheme depicting position of pin implant into the tibia. Dotted lineindicates the region of tissue analysis. FIG. 3C Xgal staining of cellsin the bone marrow cavity of Axin2^(LacZ/+) mice, 24 hours afterinjection of PBS liposomes, and FIG. 3D liposomal Wnt3a. FIG. 3E RT-PCRof peri-implant tissues collected 24 h after injection of liposomal Wntor liposomal PBS. ImageJ software was used for quantification of bandintensity. Abbreviations: bm, bone marrow. Scale bar for panels C andD=100 μm.

FIG. 4A-4L: Liposomal Wnt3a accelerates matrix mineralization and boneremodeling. Forty-eight hours after treatment, FIG. 4A in situhybridization for Collagen type I (Col1) was performed on tissuestreated with liposomal PBS, or FIG. 4B liposomal Wnt3a. FIG. 4CPicrosirius red staining for collagen matrix after treatment withliposomal PBS or FIG. 4D liposomal Wnt3a. FIG. 4E Pentachrome histology,in which bone matrix stains yellow, seen treatment with liposomal PBS orFIG. 4F liposomal Wnt3a. FIG. 4G Alkaline phosphatase (ALP) activityafter liposomal PBS or FIG. 4H liposomal Wnt3a. FIG. 4I Tartrateresistance acid phosphatase (TRAP) activity after liposomal PBS or FIG.4J liposomal Wnt3a. FIG. 4K Proliferating cell nuclear antigen (PCNA)staining after liposomal PBS or FIG. 4L liposomal Wnt3a. Scale bar forpanels A and B=100 μm, all other panels=50 μm.

FIG. 5A-5I: Liposomal Wnt3a increases in interfacial bone formationAfter 4 days, FIG. 5A aniline blue staining of interfacial bone insamples treated with liposomal PBS or FIG. 5B liposomal Wnt3a. FIG. 5CQuantification of aniline blue-stained interfacial bone onpost-injection day 4 (n=3 for liposomal Wnt3a, n=3 for liposomal PBS).FIG. 5D Pentachrome histology, in which bone matrix stains yellow, seentreatment with liposomal PBS or FIG. 5E liposomal Wnt3a. FIG. 5FAlkaline phosphatase (ALP) activity after liposomal PBS or FIG. 5Gliposomal Wnt3a. FIG. 5H Tartrate resistance acid phosphatase (TRAP)activity after liposomal PBS or FIG. 5I liposomal Wnt3a. Scale bar forpanels A and B=100 μm, all other panels=50 μm.

FIG. 6A-6I: The osteogenic advantage conferred by liposomal Wnt3a ismaintained at later stages of implant osseointegration. Eleven daysafter treatment FIG. 6A aniline blue staining of the interfacial boneformed after liposomal PBS or FIG. 6B liposomal Wnt3a. FIG. 6CQuantification of interfacial bone by aniline blue staining andhistomorphometric analyses (n=2 for each condition, p<0.01). FIG. 6DAlkaline phosphatase (ALP) activity after liposomal PBS or FIG. 6Eliposomal Wnt3a. FIG. 6F Tartrate resistance acid phosphatase (TRAP)activity after liposomal PBS or FIG. 6G liposomal Wnt3a. FIG. 6HPicrosirius red staining for collagen matrix after treatment withliposomal PBS or FIG. 6I liposomal Wnt3a. Asterisk denotes cells—but nocollagen matrix—that occupies the peri-implant space. Scale bar forpanels A and B=200 μm, panels D, E, F and G=50 μm, panels H and I=10 μm.

FIG. 7 : Treatment with liposomal Wnt3a creates a margin of safety whichallows for the protection against implant failure. As healingprogresses, the composition and strength of the interface (with orwithout L-Wnt3a) ranges from that of fibrin all the way up to that offully-dense lamellar bone. However, administration of L-Wnt3a leads toachievement of a larger strength of the interface (A) than for thecontrol case (C) at a chosen post-surgical time, say t₁. Therefore, ifimplant loading were to begin at post-surgical time t₁ and produced aninterfacial stress level B (purple dotted line), then stress B will beless than strength A of the L-Wnt3a interface but greater than strengthC of the control interface; this means that at time t₁, interface C willfail, but not interface A. In this example, the safety factor forinterface A is therefore the ratio A/B. Another view of the situation isto observe that one needs to wait until just beyond time t₂ beforeloading the control interface to a stress B, because only then would thecontrol interface have achieved a strength that's larger than stress B.The time difference t₂−t₁ represents how much earlier one could load theinterface treated with L-Wnt3a with a stress level B. One interestingadditional point is that, in general, any implant will typically producea rather complicated, spatially-varying stress state in the interface,due to geometric irregularities of the implant, placement in thesurgical site, and variations in how it is loaded during function.Therefore, the schematic plot in FIG. 7 is expected to differ from placeto place in the interface because the applied stress level B will alsodiffer from place to place.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Bone implants have been extensively employed to replace missing ordamaged hard tissues. Implants are manufactured to withstand themovement and stress associated with these clinical applications but thelifespan of implants is limited: Because they are denser and strongerthan bone, implants can eventually weaken the surrounding bone-materialinterface. When this connection between bone and the implant surface islost then the implant must be removed and replaced. In cases whereosseointegration is likely to be compromised because of a poor implantbed or underlying illness then the ability to stimulate rapid and robustosseointegration is essential. Consequently, considerable effort hasgone into developing techniques that enhance and maintainosseointegration of implants. Osseointegration occurs when cells in theperi-implant space attach to the implant surface and differentiate intomatrix-secreting osteoblasts.

In some embodiments of the invention, methods are providing forproviding an individual with a stable orthopedic or dental implant,where the method comprises introducing an orthopedic or dental implantinto an individual in need thereof; and contacting the site of theimplant with a wnt formulation comprising wnt is inserted in thenon-aqueous phase of a lipid structure, where the site of implantincludes, without limitation, the peri-implant space. The methods speedosseointegration and extend the functional lifespan of orthopedic anddental implants.

The methods of the invention provide important benefits in the field oforthopedic and dental implants. Implant stability is a function of twogeneral characteristics: the geometry of the implant and the amount andquality of the bone in which the implant is placed. When either of thesefeatures is sub-optimal then forces, even forces that are relativelysmall, can cause excessive displacement of the implant within theimplant bed. Excessive displacement causes implant motion and if thismotion is disproportionately large then the implant is considerednon-functional and must be removed.

Precisely what constitutes an excessive force, however, is difficult todefine. One reason for this problem is that the material properties ofthe implant bed are continually changing: Initially, the peri-implantspace is filled with a fibrin-rich blood clot that has a low modulus ofelasticity. Consequently, even a very small force, F, will cause a largedisplacement of the implant that in turn creates very high interfacialstrains. When this strain/force passes a certain threshold thenperi-implant cells tend to arrest their differentiation into osteoblastsand form fibrous or fibrocartilaginous tissue instead.

As the peri-implant tissue matures, the space becomes populated by cellsthat differentiate into osteoblasts and deposit a collagen-richextracellular matrix (see, for example, FIG. 4C,D). This collagen-richmatrix will have a higher modulus of elasticity than the fibrin clot,meaning that the same force, F, will elicit considerably lessdisplacement of the implant and create significantly lower interfacialstrains. Within a certain range (e.g., 10-30%) these strains resultingfrom implant loading can act as osteogenic stimuli.

In the final stages of implant osseointegration, the mineralizedperi-implant matrix undergoes remodeling through a process of mineralapposition and osteoclastic activity that eventually transforms thewoven bone into lamellar bone (see, for example, FIG. 6H,I). At thispoint, the implant is most resistant to excessive displacement. It isapparent from the clinical literature and from biomechanical testingthat the sooner the implant is stabilized by interfacial bone, the moreforce the implant can withstand without adverse effects.

The methods of the invention utilize therapeutic Wnt proteinformulations. In some embodiments of the invention, a pharmaceuticalcomposition for in vivo administration is provided, comprising atherapeutically effective dose of a Wnt protein, where the Wnt proteinis inserted in the non-aqueous phase of a lipid structure, e.g. in thesurface of a liposome, micelle, lipid raft, etc., in an emulsion, andthe like. In some embodiments the Wnt protein is presented in its activeconformation on an outer liposome membrane or micelle. Pharmaceuticalcompositions of the present invention can be administered to an animalfor therapeutic purposes. In some embodiments of the invention, thecompositions are administered locally, e.g. by injection at the site ofan injury.

In some embodiments of the invention, a pharmaceutical composition ofthe present invention is administered to an animal to accelerate bonegrowth, e.g. to enhance osseointegration of dental or orthopedicimplants, following an injury, in the treatment of bone disease, etc.

Biologically active Wnt pharmaceutical compositions retain the effectorfunctions that are directly or indirectly caused or performed by nativesequence Wnt polypeptides when administered in vivo. Effector functionsof native sequence Wnt polypeptides include stabilization of β-catenin,stimulation of stem cell self-renewal, and the like. The Wntcompositions find use in a variety of therapeutic methods, including themaintenance and growth of stem cells, tissue regeneration, and the like.

For use in the above methods, the invention also provides an article ofmanufacture, comprising: a container, a label on the container, and acomposition comprising an active agent within the container, wherein thecomposition comprises substantially homogeneous biologically active Wntprotein inserted in the non-aqueous phase of a lipid structure, which iseffective in vivo, for example in enhancing proliferation and/ormaintenance of stem or progenitor cells, and the label on the containerindicates that the composition can be used for enhancing proliferationand/or maintenance of those cells.

Definitions

Before the present methods are described, it is to be understood thatthis invention is not limited to particular methods described, as suchmay, of course, vary. It is also to be understood that the terminologyused herein is for the purpose of describing particular embodimentsonly, and is not intended to be limiting, since the scope of the presentinvention will be limited only by the appended claims.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges encompassed within the invention, subject to anyspecifically excluded limit in the stated range.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describe themethods and/or materials in connection with which the publications arecited.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “and”, and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “amicrosphere” includes a plurality of such microspheres and reference to“the stent” includes reference to one or more stents and equivalentsthereof known to those skilled in the art, and so forth.

Orthopaedic and dental biomaterial and implants. Orthopaedic and dentalbiomaterials can be implanted into or near bones to facilitate healingor to compensate for a lack or loss of bone tissue. The materials usedin orthopaedic surgery include, for example, ceramics; polymers; metals,such as stainless steel, cobalt-chromium and titanium; and restorablematerials, such as biogas, various modifications of hydroxyapatite andbone grafts. Polyethylene and polymethylmethacrylate are commonly usedin joints such as knee, elbow and hip replacements.

Wnt protein. Wnt proteins form a family of highly conserved secretedsignaling molecules that regulate cell-to-cell interactions duringembryogenesis. The terms “Wnts” or “Wnt gene product” or “Wntpolypeptide” when used herein encompass native sequence Wntpolypeptides, Wnt polypeptide variants, Wnt polypeptide fragments andchimeric Wnt polypeptides. In some embodiments of the invention, the Wntprotein comprises palmitate covalently bound to a cysteine residue.

A “native sequence” polypeptide is one that has the same amino acidsequence as a Wnt polypeptide derived from nature. Such native sequencepolypeptides can be isolated from cells producing endogenous Wnt proteinor can be produced by recombinant or synthetic means. Thus, a nativesequence polypeptide can have the amino acid sequence of, e.g. naturallyoccurring human polypeptide, murine polypeptide, or polypeptide from anyother mammalian species, or from non-mammalian species, e.g. Drosophila,C. elegans, and the like.

The term “native sequence Wnt polypeptide” includes human and murine Wntpolypeptides. Human wnt proteins include the following: Wnt 1, Genbankreference NP_005421.1; Wnt 2, Genbank reference NP_003382.1, which isexpressed in brain in the thalamus, in fetal and adult lung and inplacenta; two isoforms of Wnt 2B, Genbank references NP_004176.2 andNP_078613.1. Isoform 1 is expressed in adult heart, brain, placenta,lung, prostate, testis, ovary, small intestine and colon. In the adultbrain, it is mainly found in the caudate nucleus, subthalamic nucleusand thalamus. Also detected in fetal brain, lung and kidney. Isoform 2is expressed in fetal brain, fetal lung, fetal kidney, caudate nucleus,testis and cancer cell lines. Wnt 3 and Wnt3A play distinct roles incell-cell signaling during morphogenesis of the developing neural tube,and have the Genbank references NP_110380.1 and X56842. Wnt3A isexpressed in bone marrow. Wnt 4 has the Genbank reference NP 110388.2.Wnt 5A and Wnt 5B have the Genbank references NP_003383.1 and AK013218.Wnt 6 has the Genbank reference NP_006513.1; Wnt 7A is expressed inplacenta, kidney, testis, uterus, fetal lung, and fetal and adult brain,Genbank reference NP_004616.2. Wnt 7B is moderately expressed in fetalbrain, weakly expressed in fetal lung and kidney, and faintly expressedin adult brain, lung and prostate, Genbank reference NP_478679.1. Wnt 8Ahas two alternative transcripts, Genbank references NP_114139.1 andNP_490645.1. Wnt 8B is expressed in the forebrain, and has the Genbankreference NP_003384.1. Wnt 10A has the Genbank reference NP_079492.2.Wnt 10B is detected in most adult tissues, with highest levels in heartand skeletal muscle. It has the Genbank reference NP_003385.2. Wnt 11 isexpressed in fetal lung, kidney, adult heart, liver, skeletal muscle,and pancreas, and has the Genbank reference NP_004617.2. Wnt 14 has theGenbank reference NP_003386.1. Wnt 15 is moderately expressed in fetalkidney and adult kidney, and is also found in brain. It has the Genbankreference NP_003387.1. Wnt 16 has two isoforms, Wnt-16a and Wnt-16b,produced by alternative splicing. Isoform Wnt-16B is expressed inperipheral lymphoid organs such as spleen, appendix, and lymph nodes, inkidney but not in bone marrow. Isoform Wnt-16a is expressed atsignificant levels only in the pancreas. The Genbank references areNP_057171.2 and NP_476509.1.

The term “native sequence Wnt protein” includes the native proteins withor without the initiating N-terminal methionine (Met), and with orwithout the native signal sequence. The native sequence human and murineWnt polypeptides known in the art are from about 348 to about 389 aminoacids long in their unprocessed form reflecting variability(particularly at the poorly conserved amino-terminus and severalinternal sites), contain 21 conserved cysteines, and have the featuresof a secreted protein. The molecular weight of a Wnt polypeptide isabout 38-42 kD.

A “variant” polypeptide means a biologically active polypeptide asdefined below having less than 100% sequence identity with a nativesequence polypeptide. Such variants include polypeptides wherein one ormore amino acid residues are added at the N- or C-terminus of, orwithin, the native sequence; from about one to forty amino acid residuesare deleted, and optionally substituted by one or more amino acidresidues; and derivatives of the above polypeptides, wherein an aminoacid residue has been covalently modified so that the resulting producthas a non-naturally occurring amino acid. Ordinarily, a biologicallyactive Wnt variant will have an amino acid sequence having at leastabout 90% amino acid sequence identity with a native sequence Wntpolypeptide, preferably at least about 95%, more preferably at leastabout 99%.

A “chimeric” Wnt polypeptide is a polypeptide comprising a Wntpolypeptide or portion (e.g., one or more domains) thereof fused orbonded to heterologous polypeptide. The chimeric Wnt polypeptide willgenerally share at least one biological property in common with a nativesequence Wnt polypeptide. Examples of chimeric polypeptides includeimmunoadhesins, combine a portion of the Wnt polypeptide with animmunoglobulin sequence, and epitope tagged polypeptides, which comprisea Wnt polypeptide or portion thereof fused to a “tag polypeptide”. Thetag polypeptide has enough residues to provide an epitope against whichan antibody can be made, yet is short enough such that it does notinterfere with biological activity of the Wnt polypeptide. Suitable tagpolypeptides generally have at least six amino acid residues and usuallybetween about 6-60 amino acid residues.

A “functional derivative” of a native sequence Wnt polypeptide is acompound having a qualitative biological property in common with anative sequence Wnt polypeptide. “Functional derivatives” include, butare not limited to, fragments of a native sequence and derivatives of anative sequence Wnt polypeptide and its fragments, provided that theyhave a biological activity in common with a corresponding nativesequence Wnt polypeptide. The term “derivative” encompasses both aminoacid sequence variants of Wnt polypeptide and covalent modificationsthereof.

Biologically Active Wnt. The methods of the present invention providefor Wnt compositions that are active when administered to an animal,e.g. a mammal, in vivo. One may determine the specific activity of a Wntprotein in a composition by determining the level of activity in afunctional assay after in vivo administration, e.g. accelerating boneregeneration, upregulation of stem cell proliferation, etc.,quantitating the amount of Wnt protein present in a non-functionalassay, e.g. immunostaining, ELISA, quantitation on coomasie or silverstained gel, etc., and determining the ratio of in vivo biologicallyactive Wnt to total Wnt.

Lipid Structure. As used in the methods of the invention, lipidstructures are found to be important in maintaining the activity of wntproteins following in vivo administration. The wnt proteins are notencapsulated in the aqueous phase of these structures, but are ratherintegrated into the lipid membrane, and may be inserted in the outerlayer of a membrane. Such a structure is not predicted from conventionalmethods of formulating proteins in, for example, liposomes.

The methods used for tethering wnt proteins to the external surface of aliposome or micelle may utilize a sequence so as to emphasize theexoliposomal display of the protein, where crude liposomes are firstpre-formed; wnt protein is then added to the crude mixture, which willfavor addition of exo-liposomal wnt, followed by various formulationsteps, which may include size filtering; dialysis, and the like

Suitable lipids include fatty acids, neutral fats such astriacylglycerols, fatty acid esters and soaps, long chain (fatty)alcohols and waxes, sphingoids and other long chain bases, glycolipids,sphingolipids, carotenes, polyprenols, sterols, and the like, as well asterpenes and isoprenoids. For example, molecules such as diacetylenephospholipids may find use.

Included are cationic molecules, including lipids, synthetic lipids andlipid analogs, having hydrophobic and hydrophilic moieties, a netpositive charge, and which by itself can form spontaneously into bilayervesicles or micelles in water. The term also includes any amphipathicmolecules that can be stably incorporated into lipid micelle or bilayersin combination with phospholipids, with its hydrophobic moiety incontact with the interior, hydrophobic region of the micelle or bilayermembrane, and its polar head group moiety oriented toward the exterior,polar surface of the membrane.

The term “cationic amphipathic molecules” is intended to encompassmolecules that are positively charged at physiological pH, and moreparticularly, constitutively positively charged molecules, comprising,for example, a quaternary ammonium salt moiety. Cationic amphipathicmolecules typically consist of a hydrophilic polar head group andlipophilic aliphatic chains. Similarly, cholesterol derivatives having acationic polar head group may also be useful. See, for example, Farhoodet al. (1992) Biochim. Biophys. Acta 1111: 239-246; Vigneron et al.(1996) Proc. Natl. Acad. Sci. (USA) 93: 9682-9686.

Cationic amphipathic molecules of interest include, for example,imidazolinium derivatives (WO 95/14380), guanidine derivatives (WO95/14381), phosphatidyl choline derivatives (WO 95/35301), andpiperazine derivatives (WO 95/14651). Examples of cationic lipids thatmay be used in the present invention include DOTIM (also called BODAI)(Solodin et al., (1995) Biochem. 34: 13537-13544), DDAB (Rose et al.,(1991) BioTechniques 10(4): 520-525), DOTMA (U.S. Pat. No. 5,550,289),DOTAP (Eibl and Wooley (1979) Biophys. Chem. 10: 261-271), DMRIE(Feigner et al., (1994) J. Biol. Chem. 269(4): 2550-2561), EDMPC(commercially available from Avanti Polar Lipids, Alabaster, Alabama),DCChol (Gau and Huang (1991) Biochem. Biophys. Res. Comm. 179: 280-285),DOGS (Behr et al., (1989) Proc. Natl. Acad. Sci. USA, 86: 6982-6986),MBOP (also called MeBOP) (WO 95/14651), and those described in WO97/00241.

While not required for activity, in some embodiments a lipid structuremay include a targeting group, e.g. a targeting moiety covalently ornon-covalently bound to the hydrophilic head group. Head groups usefulto bind to targeting moieties include, for example, biotin, amines,cyano, carboxylic acids, isothiocyanates, thiols, disulfides,α-halocarbonyl compounds, α,β-unsaturated carbonyl compounds, alkylhydrazines, etc.

Chemical groups that find use in linking a targeting moiety to anamphipathic molecule also include carbamate; amide (amine pluscarboxylic acid); ester (alcohol plus carboxylic acid), thioether(haloalkane plus sulfhydryl; maleimide plus sulfhydryl), Schiff's base(amine plus aldehyde), urea (amine plus isocyanate), thiourea (amineplus isothiocyanate), sulfonamide (amine plus sulfonyl chloride),disulfide; hyrodrazone, lipids, and the like, as known in the art.

For example, targeting molecules may be formed by converting acommercially available lipid, such as DAGPE, a PEG-PDA amine, DOTAP,etc. into an isocyanate, followed by treatment with triethylene glycoldiamine spacer to produce the amine terminated thiocarbamate lipid whichby treatment with the para-isothiocyanophenyl glycoside of the targetingmoiety produces the desired targeting glycolipids. This synthesisprovides a water soluble flexible linker molecule spaced between theamphipathic molecule that is integrated into the nanoparticle, and theligand that binds to cell surface receptors, allowing the ligand to bereadily accessible to the protein receptors on the cell surfaces.

A targeting moiety, as used herein, refers to all molecules capable ofspecifically binding to a particular target molecule and forming a boundcomplex as described above. Thus the ligand and its corresponding targetmolecule form a specific binding pair.

The term “specific binding” refers to that binding which occurs betweensuch paired species as enzyme/substrate, receptor/agonist,antibody/antigen, and lectin/carbohydrate which may be mediated bycovalent or non-covalent interactions or a combination of covalent andnon-covalent interactions. When the interaction of the two speciesproduces a non-covalently bound complex, the binding which occurs istypically electrostatic, hydrogen-bonding, or the result of lipophilicinteractions. Accordingly, “specific binding” occurs between a pairedspecies where there is interaction between the two which produces abound complex having the characteristics of an antibody/antigen orenzyme/substrate interaction. In particular, the specific binding ischaracterized by the binding of one member of a pair to a particularspecies and to no other species within the family of compounds to whichthe corresponding member of the binding member belongs. Thus, forexample, an antibody preferably binds to a single epitope and to noother epitope within the family of proteins.

Examples of targeting moieties include, but are not limited toantibodies, lymphokines, cytokines, receptor proteins such as CD4 andCD8, solubilized receptor proteins such as soluble CD4, hormones, growthfactors, peptidomimetics, synthetic ligands, and the like whichspecifically bind desired target cells, and nucleic acids which bindcorresponding nucleic acids through base pair complementarity. Targetingmoieties of particular interest include peptidomimetics, peptides,antibodies and antibody fragments (e.g. the Fab′ fragment). For example,β-D-lactose has been attached on the surface to target thealoglysoprotein (ASG) found in liver cells which are in contact with thecirculating blood pool.

Cellular targets include tissue specific cell surface molecules, fortargeting to specific sites of interest, e.g. neural cells, liver cells,bone marrow cells, kidney cells, pancreatic cells, muscle cells, and thelike. For example, nanoparticles targeted to hematopoietic stem cellsmay comprise targeting moieties specific for CD34, ligands for c-kit,etc. Nanoparticles targeted to lymphocytic cells may comprise targetingmoieties specific for a variety of well known and characterized markers,e.g. B220, Thy-1, and the like.

The use of liposomes or micelles as a delivery vehicle is one method ofinterest. A liposome is a spherical vesicle with a membrane composed ofa phospholipid bilayer. Liposomes can be composed of naturally-derivedphospholipids with mixed lipid chains (like eggphosphatidylethanolamine), or of pure surfactant components like DOPE(dioleolylphosphatidylethanolamine). Liposomes often contain a core ofencapsulated aqueous solution; while lipid spheres that contain noaqueous material are referred to as micelles. As the wnt proteins arepresent in the lipid phase and not the encapsulated aqueous phase,micelles may be used interchangeably with liposome for the compositionsof the present invention. The lipids may be any useful combination ofknown liposome or micelle forming lipids, including cationic lipids,such as phosphatidylcholine, or neutral lipids, such as cholesterol,phosphatidyl serine, phosphatidyl glycerol, and the like.

In another embodiment, the vesicle-forming lipid is selected to achievea specified degree of fluidity or rigidity, to control the stability ofthe structure in serum, etc. Liposomes having a more rigid lipidbilayer, or a liquid crystalline bilayer, are achieved by incorporationof a relatively rigid lipid, e.g., a lipid having a relatively highphase transition temperature, e.g., up to 60° C. Rigid, i.e., saturated,lipids contribute to greater membrane rigidity in the lipid bilayer.Other lipid components, such as cholesterol, are also known tocontribute to membrane rigidity in lipid bilayer structures. Lipidfluidity is achieved by incorporation of a relatively fluid lipid,typically one having a lipid phase with a relatively low liquid toliquid-crystalline phase transition temperature, e.g., at or below roomtemperature.

The liposomes may be prepared by a variety of techniques, such as thosedetailed in Szoka, F., Jr., et al., Ann. Rev. Biophys. Bioeng. 9: 467(1980). Typically, the liposomes are multilamellar vesicles (MLVs),which can be formed by simple lipid-film hydration techniques. In thisprocedure, a mixture of liposome-forming lipids of the type detailedabove dissolved in a suitable organic solvent is evaporated in a vesselto form a thin film, which is then covered by an aqueous medium. Thelipid film hydrates to form MLVs, typically with sizes between about 0.1to 10 microns.

The liposomes micelles, etc. of the invention may have substantiallyhomogeneous sizes in a selected size range, typically between about 0.01to 0.5 microns, more preferably between 0.03-0.40 microns. One effectivesizing method for REVs and MLVs involves extruding an aqueous suspensionof the liposomes through a series of polycarbonate membranes having aselected uniform pore size in the range of 0.03 to 0.2 micron, typically0.05, 0.08, 0.1, or 0.2 microns. The pore size of the membranecorresponds roughly to the largest sizes of liposomes produced byextrusion through that membrane, particularly where the preparation isextruded two or more times through the same membrane. Homogenizationmethods are also useful for down-sizing liposomes to sizes of 100 nm orless.

The pharmaceutical compositions of the present invention also comprise apharmaceutically acceptable carrier. Many pharmaceutically acceptablecarriers may be employed in the compositions of the present invention.Generally, normal saline will be employed as the pharmaceuticallyacceptable carrier. Other suitable carriers include, e.g., water,buffered water, 0.4% saline, 0.3% glycine, and the like, includingglycoproteins for enhanced stability, such as albumin, lipoprotein,globulin, etc. These compositions may be sterilized by conventional,well known sterilization techniques. The resulting aqueous solutions maybe packaged for use or filtered under aseptic conditions andlyophilized, the lyophilized preparation being combined with a sterileaqueous solution prior to administration. The compositions may containpharmaceutically acceptable auxiliary substances as required toapproximate physiological conditions, such as pH adjusting and bufferingagents, tonicity adjusting agents and the like, for example, sodiumacetate, sodium lactate, sodium chloride, potassium chloride, calciumchloride, etc.

The concentration of lipid structures in the carrier may vary.Generally, the concentration will be about 0.1 to 1000 mg/ml, usuallyabout 1-500 mg/ml, about 5 to 100 mg/ml, etc. Persons of skill may varythese concentrations to optimize treatment with different lipidcomponents or of particular patients.

Compositions will comprise a therapeutically effective in vivo dose of awnt protein, and may comprise a cocktail of one or more wnt proteins.

Therapeutic Methods

Methods are providing for providing an individual with a stableorthopedic or dental implant, where the method comprises introducing anorthopedic or dental implant into an individual in need thereof; andcontacting the site of the implant with a wnt formulation comprising wntis inserted in the non-aqueous phase of a lipid structure, where thesite of implant includes, without limitation, the peri-implant space.The methods speed osseointegration and extend the functional lifespan oforthopedic and dental implants.

The wnt formulation may be delivered directly to the site of theimplant. The wnt formulation is provided immediately before, during orafter the implant is introduced, and in some embodiments is deliveredwithin 1, 2, 3, 4, 5, 6, 7 days following introduction of the implant.The wnt formulation may be transiently provided over a short, definedperiod of time, for example as a single bolus, as a continuous injectionfor a short period of time, e.g. not more than about 48 hours, not morethan about 24 hours, not more than about 12 hours, etc., as repeatedbolus doses for a short period of time, e.g. not more than about 48hours, not more than about 24 hours, not more than about 12 hours, etc.,and the like.

The methods of the invention may be applied to a wide variety ofimplants in the orthopedic and dental fields, including, for examples,hip, knee, spine and dental implants. In addition to injection of wnt,the implant may be coated with a wnt formulation of the invention priorto introduction, for example where the implant acts as a receptacle forthe formulation, which is extruded or released at the appropriate timeafter initial inflammation has subsided; where a reservoir of the wntformulation is implanted in conjunction with the implant, and the like.

The subject methods are useful for both prophylactic and therapeuticpurposes. Thus, as used herein, the term “treating” is used to refer tostabilization of implants, prevention of implant failure, and treatmentof a pre-existing condition. Evidence of therapeutic effect may be anydiminution in the severity of disease. The therapeutic effect can bemeasured in terms of clinical outcome or can be determined byimmunological or biochemical tests. Patents for treatment may bemammals, e.g. primates, including humans, may be laboratory animals,e.g. rabbits, rats, mice, etc., particularly for evaluation oftherapies, horses, dogs, cats, farm animals, etc.

The dosage of the therapeutic formulation will vary widely, dependingupon the nature of the condition, the frequency of administration, themanner of administration, the clearance of the agent from the host, andthe like. The initial dose can be larger, followed by smallermaintenance doses. The dose can be administered as infrequently asweekly or biweekly, or more often fractionated into smaller doses andadministered daily, semi-weekly, or otherwise as needed to maintain aneffective dosage level.

In some embodiments of the invention, administration of the wntpharmaceutical formulation is performed by local administration. Localadministration, as used herein, may refer to topical administration, butmore often refers to injection or other introduction into the body at asite of treatment. Examples of such administration include injection atthe site of an implant or bone weakness, and the like. It is found thatthe lipid structures of the present invention generally are lesseffective when systemically administered, and the highest activity maybe found at or around the site where it is initially introduced.

In some embodiments of the invention, the formulations are administeredon a short term basis, for example a single administration, or a seriesof administration performed over, e.g. 1, 2, 3 or more days, up to 1 or2 weeks, in order to obtain a rapid, significant increase in activity.The size of the dose administered must be determined by a physician andwill depend on a number of factors, such as the nature and gravity ofthe disease, the age and state of health of the patient and thepatient's tolerance to the drug itself.

In many clinical situations, the bone healing condition are less idealdue to decreased activity of bone forming cells, e.g. within agedpeople, following injury, in osteogenesis imperfecta, etc. Within bonemarrow stroma there exists a subset of non-hematopoietic cells capableof giving rise to multiple cell lineages. These cells termed asmesenchymal stem cells (MSC) have potential to differentiate to lineagesof mesenchymal tissues including bone, cartilage, fat, tendon, muscle,and marrow stroma.

A variety of bone and cartilage disorders affect aged individuals. Suchtissues are normally regenerated by mesenchymal stem cells. Included insuch conditions is osteoarthritis. Osteoarthritis occurs in the jointsof the body as an expression of “wear-and-tear”. Thus athletes oroverweight individuals develop osteoarthritis in large joints (knees,shoulders, hips) due to loss or damage of cartilage. This hard, smoothcushion that covers the bony joint surfaces is composed primarily ofcollagen, the structural protein in the body, which forms a mesh to givesupport and flexibility to the joint. When cartilage is damaged andlost, the bone surfaces undergo abnormal changes. There is someinflammation, but not as much as is seen with other types of arthritis.Nevertheless, osteoarthritis is responsible for considerable pain anddisability in older persons.

In conditions of the aged where repair of mesenchymal tissues isdecreased, or there is a large injury to mesenchymal tissues, the stemcell activity may be enhanced by administration of tissue regeneratingagent(s).

In methods of accelerating bone repair, a pharmaceutical wnt compositionof the present invention is administered to a patient suffering fromdamage to a bone, e.g. following an injury, or desiring increasedosteogenic activity, e.g. at the site of an implant. The formulation ispreferably administered at or near the site of desired osteogenesis,following the incident requiring bone regeneration. The wnt formulationis preferably administered for a short period of time, and in a dosethat is effective to increase the number of bone progenitor cellspresent at the site of injury. In some embodiments the wnt isadministered within about four days, three days, two days, usuallywithin about 1 day of implantation or injury, and is provided for notmore than about two weeks, not more than about one week, not more thanabout 5 days, not more than about 4 days, not more than 3 days, etc.

In an alternative method, patient suffering from damage to a bone isprovided with a composition comprising bone marrow cells, e.g. acomposition including mesenchymal stem cells, bone marrow cells capableof differentiating into osteoblasts; etc. The bone marrow cells may betreated ex vivo with a pharmaceutical composition comprising a wntprotein or proteins in a dose sufficient to enhance regeneration; or thecell composition may be administered to a patient in conjunction with awnt formulation of the invention.

The invention also provides a pharmaceutical pack or kit comprising oneor more containers filled with one or more of the ingredients of thepharmaceutical compositions of the invention. Associated with suchcontainer(s) can be a notice in the form prescribed by a governmentalagency regulating the manufacture, use or sale of pharmaceuticals orbiological products, which notice reflects approval by the agency ofmanufacture, use or sale for human administration.

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the present invention, and are not intended to limit thescope of what the inventors regard as their invention nor are theyintended to represent that the experiments below are all or the onlyexperiments performed. Efforts have been made to ensure accuracy withrespect to numbers used (e.g. amounts, temperature, etc.) but someexperimental errors and deviations should be accounted for. Unlessindicated otherwise, parts are parts by weight, molecular weight isweight average molecular weight, temperature is in degrees Centigrade,and pressure is at or near atmospheric.

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference.

The present invention has been described in terms of particularembodiments found or proposed by the present inventor to comprisepreferred modes for the practice of the invention. It will beappreciated by those of skill in the art that, in light of the presentdisclosure, numerous modifications and changes can be made in theparticular embodiments exemplified without departing from the intendedscope of the invention. Due to biological functional equivalencyconsiderations, changes can be made in protein structure withoutaffecting the biological action in kind or amount. All suchmodifications are intended to be included within the scope of theappended claims.

EXPERIMENTAL EXAMPLE 1

A protein-based strategy to stimulate implant osseointegration isprovided. A pro-osteogenic effect is achieved by Wnt signals thatpromote osteoblast activation, inhibit osteoclast activity, andstimulate the differentiation of pluripotent stem cells towards anosteoblast cell fate.

Methods and Materials

In vivo Wnt responsiveness. Axin2^(LacZ/+) mice were bred as describedand the LacZ product, β-galactosidase, was detected by X-gal staining.Tissues were embedded in OCT followed by cryo-sectioning, then fixedwith 0.2% glutaraldehyde for 15 min and stained with Xgal overnight at37° C.

Implant Surgery. All procedures followed protocols approved by theStanford Committee on Animal Research. Adult mice (males, between 3-5months old) were anaesthetized with an intraperitoneal injection ofKetamine/Xylazine. An incision was made over the right anterior-proximaltibia and the tibial surface of the knee was exposed while theperiosteal surface was preserved. A stainless steel needle (Precisionglide Needle 27½, Beckton Dickinson, N.J.) with diameter of 0.4 mm wascut to obtain a 6 mm length, and the top of the needle was bent at a 90°angle approximately 1 mm down. The needle was used as an implant in ourmodel and was carefully driven through the knee into the bone marrow ofthe tibia. Lastly, the wounds were sutured closed with non-absorbablesutures and antibiotics and analgesics were subsequently given to theanimals. Animals were housed in a temperature-controlled environmentwith 12-hour light dark cycles and were given food and water ad libitum.

Molecular and cellular assays. Under RNase-free conditions tibiae wereharvested, the skin and outer layers of muscle were removed, the tissueswashed in 1× PBS at 4° C. and then fixed in 4% paraformaldehyde. Theimplant was carefully removed and the tissues were decalcified in aheat-controlled microwave in 19% EDTA, after which the tibia wasprepared for paraffin embedding. Paraffin embedding followed standardprotocols and sections were generated at an 8-μm thickness. For in situhybridization, the relevant digoxigenin-labeled mRNA anti-sense probeswere prepared from cDNA templates for Runx2, Collagen type I, Collagentype IV and Osteocalcin. Sections were de-waxed, treated with ProteinaseK, and incubated in hybridization buffer containing the relevantriboprobe. Probe was added at an approximate concentration of 0.25μg/mL. Stringency washes of saline sodium citrate solution were done at52° C., and further washed in maleic acid buffer with 1% Tween 20.Slides were treated with Anti-DIG antibody (Roche). For color detection,slides were incubated in nitro blue tetrazolium chloride (NBT; Roche)and 5-bromo-4-chloro-3-indolyl phosphate (BCIP; Roche). Afterdeveloping, the slides were cover-slipped with aqueous mounting medium.For immunostaining, tissue sections were de-waxed followed by immersionin H₂O₂/PBS, washed in PBS, incubated in ficin (Zymed), treated with 0.1M glycine, washed further, and then blocked in ovalbumin (Worthington)and 1% whole donkey IgG (Jackson ImmunoResearch). Appropriate primaryantibody was added and incubated overnight at 4° C., then washed in PBS.Samples were incubated with peroxidase-conjugated secondary antibody(Jackson ImmunoResearch) for an hour and a DAB substrate kit (VectorLaboratories) was used to develop the color reaction. Some commonly usedantibodies include proliferating cell nuclear antigen (PCNA, Zymed) andplatelet endothelial cell adhesion molecule 1 (PECAM-1, BD Biosciences).For tartrate-resistant acid phosphatase (TRAP) staining, tissue sectionswere de-waxed and then treated with a TRAP staining kit (Sigma).

Histology and histomorphometric analyses. Pentachrome and aniline bluestaining were performed; slides were mounted with Permount afterdehydration in a series of ethanol and xylene. To quantify new bone, the1.0 mm circular mono-cortical defect was represented acrossapproximately 160, 8 μm-thick tissue sections. Out of those 160 sectionswe used a minimum of 6 slides (4 sections/slide) to quantify the amountof aniline blue-stained new osteoid matrix. Tissue sections werephotographed using a Leica digital imaging system (5× objective). Theresulting digital images were analyzed with Adobe Photoshop CS2software. We chose a fixed, rectangular region of interest (ROI) that inall images corresponded to 10⁶ pixels. The injury site was alwaysrepresented inside this ROI by manually cropping the correct size andposition of each image. Aniline blue-positive pixels were automaticallyselected using the magic wand tool set to a color tolerance of 60. Thistolerance setting resulted in highlighted pixels with a range of bluethat corresponded precisely with the histological appearance of newosteoid tissue in the aniline blue-stained sections. Cortical surfaces,or bone fragments resulting from the drill injury, were manuallydeselected. The total number of aniline blue-positive pixels for eachsection was then recorded. The pixel counts from individual sectionswere averaged for each tibia sample and the differences within and amongtreatment groups were calculated based on these averages.

Liposomal preparation and delivery.1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC; Sigma, cat #850345C)in chloroform was dried to a thin film in a 10 mL round bottom flask.Purified Wnt3a with a concentration of 1-1.3 μg/mL was mixed with driedDMPC. The lipid-Wnt3a solution was extruded 40 times through a 100-200nm polycarbonate membrane in a thermo-barrel extruder, keeping thetemperature constant at 30-32° C. (Avanti Polar Lipids, Inc). Thesupernatant was removed and the liposome pellet was re-suspended in 1×DMEM (Mediatech, Inc., Herndon, Va.). Liposomes were stored at 4° C. andused within 10 days of preparation. The liposomal preparation had aneffective Wnt3a concentration between 0.8-1.0 μg/mL, and a single (10μL) dose of this solution was delivered to the injury site by injection.

Mono-cortical tibial defects were treated with liposomal Wnt3apreparation (L-Wnt3a) by injecting 10 μL of liposomal Wnt3a into theinjury site at post-surgical day 3. An incision was made over the rightanterior-proximal tibia and the knee was exposed. Liposomes wereinjected by driving a needle through the knee adjacent to the implant.The wounds were closed with non-absorbable sutures.

RT-PCR. For gene expression analyses, tissues were homogenized inTRIzol® (Invitrogen), and RNA was isolated using RNeasy® mini column(Qiagen). Reverse transcription was performed using SuperScript IIIFirst-Strand Synthesis SuperMix for RT-PCR (Invitrogen). PCR reactionswere performed and monitored using StepOnePlus Real-Time PCR System.Normalized expression levels reported were calculated based ondifferences between threshold cycles for the gene of interest, and thehouse-keeping gene β-actin. The following primer sets were used:β-actin, sense 5′-ggaatgggtcagaaggactc-3′, antisense5′-CATGTCGTCCCAGTTGGTAA-3′ (SEQ IDS NO:1) (110); Ki67 sense5′-GCCAGCCCCGCTGATACACC-3′ (SEQ ID NO.:2) antisense5′-TTCCCTGGAGACTGGGGCCA-3′ (SEQ ID NO:3), Collagen type I, sense5′-GCCTCCCAGAACATCACCTAT-3′ (SEQ ID NO:4), antisense5′-AATTCCTGGTCTGGGGCA-3′ (SEQ ID NO:5) and Runx2, sense5′-ATTAACCCTCACTAAAGGGACCCACGGCCCTCCCTGAACT-3′ (SEQ ID NO:6), antisense5′-TAATACGACTCACTATAGGGGCCGAGGGACATGCCTGACG-3′ (SEQ IDS NO:7). InAxin2^(LacZ/+) mice, the following primers were used: sense5′-TTGATAAGGTCCTGGCAACTC-3′ (SEQ ID NO:8); antisense5′-GCGAACGGCTGCTTATTT-3′ (SEQ ID NO:9).

Statistical Analyses. A Student's t-test was used to test forsignificant differences between data sets. To create histograms themeans of data sets were calculated, and error bars in histogramsrepresented standard deviation. P-values under 0.05 were consideredsignificant.

Results

Endogenous Wnt signaling and endosteal bone homeostasis.Osseointegration occurs when cells in the peri-implant space attach tothe implant surface and differentiate into matrix-secreting osteoblasts.In our implant model, peri-implant cells originate from the endosteumand bone marrow cavity; consequently, our first objective was toidentify cells in these regions that were capable of responding to a Wntstimulus. Axin2 is a direct, cell-type independent target of Wntsignaling. In Axin2^(LacZ/+) mice, LacZ expression is driven by Axin2regulatory sequences and the LacZ product, beta galactosidase, isdetectable by Xgal staining. Therefore, Axin2^(LacZ/+) mice function asin vivo reporters of Wnt signaling activity in the bone marrow cavity.

Using Axin2^(LacZ/+) mice we found that the endosteal surfaces in theadult skeleton (FIG. 1A) were populated by Xgal positive cells (FIG.1B). Wnt responsive cells also covered the surfaces of bone trabeculaeprojecting into the marrow cavity (FIG. 1C). Some, but not all, Wntresponsive cells co-localized with sites of alkaline phosphatase (ALP)activity (FIG. 1D), an early marker of osteoprogenitor celldifferentiation.

Wnt/β-catenin signaling controls the differentiation and activity ofosteoclasts but we found minimal overlap between tartrate resistant acidphosphatase (TRAP) activity and Xgal-positive staining in the endosteum(FIG. 1E). Pericytes and endothelial cells have also been reported to beresponsive to Wnt signals, but immunostaining for collagen type IV andplatelet endothelial cell adhesion molecule (PECAM) did not coincidewith Xgal staining (FIG. 1F and data not shown). Using Runx2 (FIG. 1G),Collagen type I (FIG. 1H), and Osteocalcin (FIG. 1I) as molecularmarkers of osteo-progenitor cells and committed osteoblasts, we foundthat Runx2 and Oc mRNAs generally co-localized with sites of Xgalstaining. Thus in an intact adult skeleton, sites of Wnt signalingcorresponded most closely to sites of osteo-progenitor activity ratherthan osteoclast activity or endothelial cells/pericytes.

Dkk1-mediated endosteal bone resorption. To understand the role of Wntsignaling in the endosteum, we first inhibited Wnt signaling in bonesusing adenoviral over-expression of the soluble Wnt antagonist Dkk1. Wepreviously employed this strategy to transiently inhibit Wnt signalingwithin the adult bone marrow cavity. Control mice were treated with anadenoviral vector expressing the murine IgG2αFc fragment (Ad-Fc).

We examined control and Ad-Dkk1 treated mice on post-injection day 6(n=3 for Ad-Fc; n=6 for Ad-Dkk1) and on post-injection day 8 (n=6 forAd-Fc; n=8 for Ad-Dkk1). Ad-Dkk1 treatment of the bone marrow cavitydramatically increased TRAP staining on the endosteal (compare FIG. 2Aand B) and periosteal (compare FIG. 2C and D) surfaces of all treatedbones. We also noted a difference in vascularization, with Ad-Dkk1 miceshowing more PECAM positive cells within the bone marrow cavity (FIG.2E,F). Only subtle alterations in ALP activity were detectable in theendosteum (FIG. 2G,H) and periosteum (FIG. 2I,J) of Ad-Fc animalscompared to the Ad-Dkk1 treated animals. Collectively, these dataindicate that inhibiting endogenous Wnt signaling in the adult skeletonresults in robust osteoclast activity and bone resorption.

Liposomal Wnt3a and endosteal osteo-progenitor cell responses. In recentstudies we found that addition of exogenous Wnt3a protein to a skeletalinjury site stimulates bone regeneration. We reasoned that theperi-implant environment was like an early injury site in that it wouldbe populated by Wnt-responsive bone marrow-derived skeletal progenitorcells. We tested this hypothesis by placing a pin into theintramedullary space (FIG. 3A) and then delivering liposomal Wnt3a (orPBS in an identical liposomal carrier) to the peri-implant space (FIG.3B).

Using Axin2^(LacZ/+) mice we confirmed that liposomal Wnt3a treatmentelicited an increase in Wnt responsiveness within the marrow cavity(compare control, FIG. 3C with D). Using RT-PCR we interrogatedperi-implant tissues and found that relative to mice treated withliposomal PBS, mice treated with liposomal Wnt3a showed an up regulationin the genes encoding Runx2 and the cell proliferation marker Ki67 (24 htime point, FIG. 3E). These data indicate the liposomal Wnt treatmentstimulated a subset of cells in the bone marrow cavity to proliferateand up regulate the expression of osteo-progenitor genes.

Mice treated with liposomal Wnt3a initially showed lower Collagen type Iexpression at the 24 h time point than mice treated with liposomal PBS(FIG. 3E) but this finding was quickly reversed: by the 48 h time pointCollagen type I was significantly up regulated in peri-implant tissuestreated with liposomal Wnt3a (compare control, FIG. 4A with B). Inaddition to increased Collagen type I expression we used picrosirius redstaining and polarized light and observed a collagen-rich matrix aroundWnt-treated pins, which was absent in PBS controls (FIG. 4C,D).

Liposomal Wnt3a treatment also accelerated the organization of theperi-implant extracellular matrix. In PBS controls, the peri-implanttissue at the 48 h time point closely resembled the unperturbed bonemarrow (compare FIG. 4E with FIG. 1A) while the Wnt-treated peri-implanttissues already exhibited a circumferential arrangement around the pinimplant (FIG. 4F). Compared with PBS-treated controls, ALP activity wasalso elevated in Wnt-treated samples (FIG. 4G,H). ALP and TRAP activitywere co-localized in samples treated with liposomal Wnt3a, indicatingactive remodeling; in contrast, peri-implant tissues treated with PBSshowed only very low levels of TRAP activity (FIG. 4I,J). LiposomalWnt3a treatment also resulted in increased cell proliferation inperi-implant tissues compared to controls (FIG. 4K,L). Collectively,these data demonstrate that cells within the peri-implant space respondto liposomal Wnt3a by increasing their rate of proliferation, andaccelerating their differentiation into matrix-secreting osteoblasts.

Liposomal Wnt3a and peri-implant bone formation. Does liposomal Wnt3aresult in faster bone apposition surrounding the implant? Using anilineblue staining and histomorphometric measurements we quantified theamount of new bone matrix around the pins at the 96 h time point.Compared to controls, we found that sites treated with liposomal Wnt3aexhibited more interfacial bone (FIG. 5A,B), and histomorphometricanalyses demonstrated 3.77 times more bone in the Wnt treatedperi-implant region compared to controls (FIG. 5C). In liposomal Wnt3asamples the newly regenerated bone was directly opposed to the pinsurface; in PBS samples, peri-implant bone formation was still lacking(FIG. 5D,E).

Liposomal Wnt3a accelerated the program of interfacial bone healing. Atthis 96h time point ALP (FIG. 5F) and TRAP activity (FIG. 5H) werefinally co-expressed in PBS-treated samples. Liposomal Wnt3a samplescontinued to show evidence of ALP (FIG. 5G) and TRAP activity (FIG. 5I),indicating that active bone remodeling is supported by Wnt treatment.Thus, liposomal Wnt3a treatment accelerates interfacial bone depositionand remodeling around a pin implant.

Liposomal Wnt3a and maintenance of the osseointegration state. At earlystages of osseointegration, liposomal Wnt3a treatment accelerates boneformation but is this advantage maintained at later time points? Toanswer this question we collected tibiae two weeks after pin placementand used aniline blue staining (FIG. 6A,B) and histomorphometricmeasurements to assess the amount of bone that remained around the pins.We found that mice treated with liposomal Wnt3a still had significantlymore peri-implant bone than PBS-treated controls (FIG. 6C). Both controland Wnt-treated samples still showed continued evidence of boneremodeling by ALP (FIG. 6D,E) and TRAP activity (FIG. 6F,G) but therewas another compelling difference between the two groups: PBS-treatedsamples still had a band of fibrous connective tissue (marked byasterisks in FIG. 6H; also see asterisks in FIG. 6A) that separated themineralized osteoid matrix and the pin surface. In contrast, Wnt-treatedsamples exhibited a mineralized osteoid matrix in tight proximity to thepin surface (FIG. 6I). An abundant literature indicates that thisinterfacial bone is directly responsible for implant stability.

It has become increasingly clear that biological approaches may bebeneficial for implant osseointegration. including the Wnt family ofsecreted growth factors. The ability to purify Wnt proteins and packagethem for in vivo use has provided a unique opportunity to directly testWnt protein as an osteo-inductive agent for osseointegration.

Endogenous Wnt signaling regulates multiple phases of the skeletogenicprogram but it is unsagacious to assume that the function of Wntsignaling would be equivalent among all of these cell types and acrossall of these stages of skeletogenic differentiation. To that end, wefirst identified the Wnt responsive cells that exist within theperi-implant environment, then directly tested the effects of inhibitingWnt signaling in that same location, and at that same developmental age.

We find that cells in the fibrous periosteum and cells lining theendosteal surfaces of long bones retain their Wnt responsivenessthroughout adulthood (FIG. 1 ). We were particularly interested in theidentities of the Wnt responsive cells within the bone marrow cavity.Wnt responding cells are identifiable using Xgal staining ofAxin2^(LacZ/+) tissue sections and for the most part, Xgal stainingpatterns overlapped with the staining patterns for ALP activity (FIG. 1). The co-expression of a number of osteogenic genes further suggestedthat most Wnt responsive cells in the adult skeleton are part of theosteo-progenitor lineage. In addition, there is growing evidence that apopulation of Wnt responsive cells within the bone marrow cavityactually comprise the osteoblast stem cell niche. If true, then inaddition to their contribution to bone regeneration these marrow-derivedWnt responsive cells should be able to contribute to the repair ofcartilage, muscle, and connective tissue injuries.

When endogenous Wnt signaling is blocked by over-expression of the Wntinhibitor Dkk1, we find a dramatic increase in osteoclastic boneresorption (FIG. 2 ). A similar finding occurs in humans with multiplemyeloma, where the severe osteolysis and pathological bone resorption isattributed to Dkk1-mediated inhibition in Wnt signaling in the bonemarrow cavity. In some experimental models of multiple myeloma boneresorption can be blocked by function-blocking anti-Dkk1 antibodies.Bone resorption can also be reversed by subsequent delivery ofconditioned media from Wnt-expressing cells. This is in keeping with ourdata showing that liposomal Wnt3a stimulates bone regeneration withinthe bone marrow cavity.

Wnt signaling and adult bone homeostasis. Injury stimulates endogenousWnt signaling. This injury response is highly conserved throughoutevolution and is essential for even the most primitive of healingresponses. Liposomal Wnt3a treatment transiently amplifies the normalWnt response to injury, which occurs after fractures, drilling, and mostimportantly for this work, implant placement (FIG. 3 ). Wnt signaling isnecessary for bone formation in the marrow cavity, but a key feature ofthis pro-osteogenic response is its duration. We found that a constantWnt signal, caused by an activating mutation in the Wnt Lrp5 receptor,is detrimental for adult bone healing after injury due to anuncontrolled proliferative response from osteo-progenitor cells in thewound site. Therefore, an approach that makes use of the Wnt pathway tostimulate implant osseointegration must take into account the stricttemporal and spatial duration of Wnt signaling.

Augmentation of bone formation with liposomal Wnt3a. We find thatliposomal Wnt3a treatment up regulates transcription of a Wnt-dependentLacZ transgene in peri-implant tissues, and stimulates the proliferationof Runx2-expressing cells (FIG. 3 ). Twenty-four hours after delivery,we find that liposomal Wnt-treated tissues show higher levels ofCollagen type I expression and the deposition of a collagenousmineralized matrix (FIG. 4 ), which by post-treatment day 4 has resultedin almost 3.8 times more peri-implant bone than controls (FIG. 5 ). Evenat later stages, we find an osteogenic advantage of having treated animplant site with liposomal Wnt3a (FIG. 6 ). The optimal time for Wnttreatment in this system was found to be three days followingimplantation.

Biomechanical safety margin. A biomechanical safety margin would providea measure of protection that could have significant long-term benefitsover the lifespan of an implant. When bone forms more rapidly and withhigher density after an implant is placed, the implant is moreeffectively shielded from excessive strain (FIG. 7 ). As healingprogresses, the composition and strength of the interface ranges fromthat of fibrin all the way up to that of dense lamellar bone. Theadministration of liposomal Wnt3a leads to a stronger implant-tissueinterface at an earlier time point than for control cases. Therefore, asafety margin is created, because at any given post surgical time,liposomal Wnt3a offers an advantage of increased strength that may beenough to prevent the implant failure that would otherwise be likely ina control case. This safety margin not only protects from implantfailure at certain loads, but also allows the implant to be loaded at anearlier time point.

The lifespan of an implant is largely determined by the untoward effectsof wear debris and excessive loading, both of which are characterized bya shift in peri-implant tissues away from a mineralized bone tissuetowards a fibrous or fibrocartilaginous tissue. The fibrousencapsulation of a failed implant demonstrates that peri-implant spaceretains the capacity to de-differentiate from matrix-secretingosteoblasts into fibrous or fibrocartilaginous cell types. Our datademonstrate that transient exposure to a Wnt3a stimulus inducesperi-implant cells to rapidly adopt an osteogenic cell fate. Afterremoval of excessive forces, this fibrous tissue could be converted intobony tissue by exposing peri-implant cells to liposomal Wnt3a.

What is claimed is:
 1. A method of accelerating osteogenesis in amammal, the method comprising: administering to the mammal an effectivedose of a wnt polypeptide comprising a lipid moiety at a site of desiredosteogenesis in the mammal, wherein the wnt protein is inserted in thenon-aqueous phase of a lipid structure.
 2. The method of claim 1,wherein the site of desired osteogenesis is the site of a bone injury.3. The method of claim 1, wherein the site of desired osteogenesis isthe site of a dental or orthopedic implant.
 4. The method of claim 3,wherein the site is a peri-implant space.
 5. The method of claim 3,wherein the wnt polypeptide is administered within 5 days afterintroduction of the implant.
 6. The method of claim 3, wherein the wntpolypeptide is administered within 3 days after introduction of theimplant.
 7. The method of claim 2, wherein the wnt polypeptide isadministered within 3 days of the injury.
 8. The method of claim 1,wherein the wnt polypeptide is administered for not more than two weeks.9. The method of claim 1, wherein the wnt polypeptide is administeredfor not more than one week.
 10. The method of claim 1, wherein the wntpolypeptide is administered for not more than 3 days.
 11. The method ofclaim 3, wherein the wnt polypeptide is administered by injection. 12.The method of claim 3, wherein the wnt polypeptide is released from theimplant.
 13. The method of claim 3, wherein the wnt polypeptide isimplanted in a reservoir at the site of the orthopedic or dentalimplant.
 14. The method of claim 1 where the wnt polypeptide is wnt 3A.15. The method of claim 1, wherein the mammal is a human.
 16. The methodof claim 15, wherein the wnt polypeptide is human wnt 3A.